SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 2,400 shares of the business’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00. Following the transaction, the insider owned 281,452 shares of the company’s stock, valued at approximately $1,370,671.24. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Philippe Menu also recently made the following trade(s):
- On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
- On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $2,912.32.
SOPHiA GENETICS Stock Performance
Shares of SOPH stock opened at $4.73 on Friday. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm has a fifty day moving average price of $4.76 and a 200 day moving average price of $4.68. The company has a market cap of $323.96 million, a P/E ratio of -9.27 and a beta of 1.04. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.
Institutional Investors Weigh In On SOPHiA GENETICS
A number of institutional investors and hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $6,708,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $2,009,000. Finally, 1492 Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $973,000. 31.59% of the stock is owned by hedge funds and other institutional investors.
Key Stories Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: Large institutional buying: UBS Asset Management and Akre Capital materially increased positions recently (UBS added ~5.4M shares). That sizable institutional demand can support the stock and offsets some insider selling. MarketBeat Institutional/Insider Summary
- Neutral Sentiment: Multiple senior executives (CEO Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma, President Ross Muken and others) executed several small sales (roughly 600–2,700 shares each) under Rule 10b5‑1 plans to cover tax withholding tied to vesting awards; these are disclosed in SEC Form 4 filings. Representative SEC filing (CEO): CEO Form 4
- Neutral Sentiment: Analyst views are mixed but skew positive: Guggenheim and BTIG have reiterated/raised targets to ~$7 with buy ratings, while one service retains a sell. Those analyst targets imply upside vs. current levels and help explain why institutional buyers remain active. Analyst Coverage
- Negative Sentiment: Collective insider selling can create short‑term downward pressure — even though each trade is small and pre‑arranged, the clustered timing (multiple execs selling within the same days) contributed to intraday selling and likely drove the price lower. Summary of the insider trade reports: InsiderTrades article
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.00.
View Our Latest Report on SOPHiA GENETICS
SOPHiA GENETICS Company Profile
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Further Reading
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
